SCHEMBL12371976

SCHEMBL12371976

Cc1cccc2cnc(-c3nccs3)nc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 2/20 0.41
PIM3 Q86V86 2/20 0.41
PIM2 Q9P1W9 2/20 0.41
JUN P05412 1/20 0.39
MAPK8 P45983 1/20 0.39
MAPK10 P53779 1/20 0.39
RAB9A P51151 2/20 0.39
PDPK1 O15530 1/20 0.39
CYP2A6 P11509 1/20 0.38
NPC1 O15118 1/20 0.37
PKM P14618 1/20 0.37
RECQL P46063 1/20 0.37
SRC P12931 2/20 0.36
SYK P43405 2/20 0.36
CDK2 P24941 1/20 0.36
ZAP70 P43403 1/20 0.36
CYP17A1 P05093 1/20 0.36
LOXL2 Q9Y4K0 1/20 0.35
ADORA2A P29274 1/20 0.35
BDKRB2 P30411 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1710374 0.81 HPGDS (0.42) PIM1PIM3PIM2RAB9ANPC1
SCHEMBL17691567 0.72 KMT2A (0.48) RAB9ANPC1RECQLKDR
SCHEMBL1710223 0.72 METAP2 (0.39) PIM1PIM3PIM2JUNMAPK8
SCHEMBL1289875 0.71 PDPK1 (0.50) RAB9APDPK1CYP2A6NPC1PKM
SCHEMBL12371974 0.70 MAP4K1 (0.44) PIM1PIM3PIM2
SCHEMBL8404376 0.69 CYP2A6 (0.39) CYP2A6ADORA2A
SCHEMBL12371980 0.68 GAA (0.49) PIM1PIM3PIM2RAB9ANPC1
SCHEMBL11211014 0.67 PDPK1 (0.46) RAB9APDPK1CYP2A6NPC1PKM
SCHEMBL856477 0.66 EGFR (0.39) CYP2A6
SCHEMBL19466048 0.66 PARP1 (0.37) CYP2A6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8759338-B2 Heterocyclic kinase inhibitors NOVARTIS AG (CH) 2014-06-24 US disclosed
US-20110195956-A1 Heterocyclic Kinase Inhibitors NOVARTIS AG (CH) 2011-08-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110195956-A1 Heterocyclic Kinase Inhibitors PIM1, PIM2, PIM3 PIM1 1/4885PIM3 3/4885PIM2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.